Keiichi Kuwano

429 citations

9 papers · 358 indexed · h-index 6

Co-authors: Kenji Kuwabara Tetsuo Asaki Taisuke Hamamoto Asami Hashino Tetsuhiro Yamada Kumiko Noda Keith Morrison Martine Clozel
Topics: Pulmonary Hypertension Research and Treatments (5 papers)Nitric Oxide and Endothelin Effects (3 papers)Inflammatory mediators and NSAID effects (3 papers)
Cited by: Cardiology and Cardiovascular Medicine Pulmonary and Respiratory Medicine Biochemistry
Journals: PLoS ONE Journal of Medicinal Chemistry Journal of Pharmacology and Experimental Therapeutics
Partner nations: Japan Switzerland

In The Last Decade

Keiichi Kuwano

9 papers receiving 342 citations

Peers

Countries citing papers authored by Keiichi Kuwano

Since Specialization

Citations

This map shows the geographic impact of Keiichi Kuwano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keiichi Kuwano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keiichi Kuwano more than expected).

Fields of papers citing papers by Keiichi Kuwano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keiichi Kuwano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keiichi Kuwano. The network helps show where Keiichi Kuwano may publish in the future.

Co-authorship network of co-authors of Keiichi Kuwano

This figure shows the co-authorship network connecting the top 25 collaborators of Keiichi Kuwano. A scholar is included among the top collaborators of Keiichi Kuwano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keiichi Kuwano. Keiichi Kuwano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Antiproliferative effect of selexipag active metabolite MRE‐269 on pulmonary arterial smooth muscle cells from patients with chronic thromboembolic pulmonary hypertension 2023 ·Pulmonary Circulation ·(unknown),(unknown),(unknown),(unknown),Yuji Ohno,(unknown),(unknown),(unknown),Keiichi Kuwano	1
2	The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats 2020 ·PLoS ONE ·(unknown),(unknown),(unknown),(unknown),(unknown),Keiichi Kuwano	8
3	A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries 2016 ·European Journal of Pharmacology ·(unknown),Kohji Murakami,(unknown),(unknown),(unknown),(unknown),Michiko Oka,Keiichi Kuwano	15
4	Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension 2015 ·Journal of Medicinal Chemistry ·Tetsuo Asaki,Keiichi Kuwano,Keith Morrison,John Gatfield,Taisuke Hamamoto,Martine Clozel	69
5	A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic Acid (MRE-269), on Rat Pulmonary Artery 2008 ·Journal of Pharmacology and Experimental Therapeutics ·Keiichi Kuwano,Asami Hashino,Kumiko Noda,(unknown),Kenji Kuwabara	72
6	Structure–activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists 2007 ·Bioorganic & Medicinal Chemistry ·Tetsuo Asaki,Taisuke Hamamoto,Yukiteru Sugiyama,Keiichi Kuwano,Kenji Kuwabara	45
7	Structure–activity relationship study on the 6-membered heteroaromatic ring system of diphenylpyrazine-type prostacyclin receptor agonists 2007 ·Bioorganic & Medicinal Chemistry Letters ·Tetsuo Asaki,Taisuke Hamamoto,Yukiteru Sugiyama,Keiichi Kuwano,Kenji Kuwabara,Tomoko Niwa	5
8	2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug 2007 ·Journal of Pharmacology and Experimental Therapeutics ·Keiichi Kuwano,Asami Hashino,Tetsuo Asaki,Taisuke Hamamoto,Tetsuhiro Yamada,(unknown),Kenji Kuwabara	141
9	Role of protein kinase C in the reduction of infarct size by N‐methyl‐1‐deoxynojirimycin, an α‐1,6‐glucosidase inhibitor 2001 ·British Journal of Pharmacology ·(unknown),Shinya Minatoguchi,(unknown),Yoshihiro Uno,Yoshio Nishida,Kazuaki Hashimoto,Ningyuan Wang,Genzou Takemura,Takako Fujiwara,(unknown),Keiichi Kuwano,Hisayoshi Fujiwara	2

About Keiichi Kuwano

Keiichi Kuwano is a scholar working on Biochemistry, Internal Medicine and Pharmacology, having authored 9 papers that have together received 358 indexed citations. Recurring topics across this work include Pulmonary Hypertension Research and Treatments (5 papers), Nitric Oxide and Endothelin Effects (3 papers) and Inflammatory mediators and NSAID effects (3 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (160 citations), Pulmonary and Respiratory Medicine (224 citations) and Biochemistry (40 citations). Keiichi Kuwano has collaborated with scholars based in Japan and Switzerland. Frequent co-authors include Kenji Kuwabara, Tetsuo Asaki, Taisuke Hamamoto, Asami Hashino, Tetsuhiro Yamada, Kumiko Noda, Keith Morrison, Martine Clozel, John Gatfield and Yukiteru Sugiyama. Their work appears in journals such as PLoS ONE, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact